Segment Information

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Information

13. Segment Information

The Company operates in two operating and reportable segments, Sorrento Therapeutics and Scilex. With the exception of unrestricted cash balances, the Company’s Chief Operating Decision Maker does not regularly review asset information by reportable segment and, therefore, it does not report asset information by reportable segment. The majority of long-lived assets for both segments are located in the United States.

The following table presents information about the Company’s reportable segments for the three and six months ended June 30, 2022 and 2021 (in thousands):

	Three Months Ended June 30,
	2022									2021
	Sorrento Therapeutics			Scilex			Total			Sorrento Therapeutics			Scilex			Total
External revenues	$	3,535		$	7,926		$	11,461		$	5,709		$	7,802		$	13,511
Operating expenses		109,709			20,113			129,822			98,553			15,508			114,061
Operating loss		(106,174	)		(12,187	)		(118,361	)		(92,844	)		(7,706	)		(100,550	)
Unrestricted cash		63,470			6,875			70,345			72,252			5,039			77,291

	Six Months Ended June 30,
	2022									2021
(in thousands)	Sorrento Therapeutics			Scilex			Total			Sorrento Therapeutics			Scilex			Total
External revenues	$	15,107		$	14,738		$	29,845		$	12,978		$	14,788		$	27,766
Operating expenses		219,359			35,730			255,089			180,430			32,791			213,221
Operating loss		(204,252	)		(20,992	)		(225,244	)		(167,452	)		(18,003	)		(185,455	)
Unrestricted cash		63,470			6,875			70,345			72,252			5,039			77,291